Dyadic International (NASDAQ:DYAI) Shares Cross Above 50 Day Moving Average – Should You Sell?

Dyadic International, Inc. (NASDAQ:DYAI)’s stock price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.40 and traded as high as $1.87. Dyadic International shares last traded at $1.74, with a volume of 88,001 shares.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Dyadic International in a research report on Thursday, November 14th.

Dyadic International Stock Performance

The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.54. The stock has a market capitalization of $51.48 million, a PE ratio of -7.56 and a beta of 0.88. The firm has a 50 day moving average price of $1.40 and a 200-day moving average price of $1.39.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.06. The business had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same period in the previous year, the business posted ($0.06) EPS. Research analysts expect that Dyadic International, Inc. will post -0.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. lifted its stake in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 868,301 shares of the biotechnology company’s stock after buying an additional 21,000 shares during the quarter. Chapin Davis Inc. owned approximately 2.97% of Dyadic International worth $903,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.